Patents by Inventor Alastair B. Selkirk

Alastair B. Selkirk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Long acting calcium channel blocker composition
    Patent number: 5209933
    Abstract: There is disclosed an improved long acting sustained release pharmaceutical composition for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binder, which are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter, are provided with a coating to obtain slow, sustained release of a safe, therapeutically effective amount of the calcium channel blocker over a period of at least about 24 hours. Thus, the improved pharmaceutical composition for a dihydropyridine calcium channel blockers is suitable for once daily administration.
    Type: Grant
    Filed: September 13, 1991
    Date of Patent: May 11, 1993
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Calum B. MacFarlane, Alastair B. Selkirk, John R. Langridge, Michael J. Dey
  • Long acting nicardipine hydrochloride formulation
    Patent number: 5198226
    Abstract: A long acting sustained release pharmaceutical composition for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binder are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter.
    Type: Grant
    Filed: November 12, 1991
    Date of Patent: March 30, 1993
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Calum B. MacFarlane, Alastair B. Selkirk, Michael J. Dey
  • Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl )piperazine
    Patent number: 5063220
    Abstract: A pharmaceutical formulation suitable for parenteral (preferably intravenous) administration includes an effective amount of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]p iperazine and a suitable amount of an acid to generate a pharmaceutically acceptable salt having a pH above about 3.0 and a solubility above about 4.0 mg/ml. The intravenous formulation optionally includes a suitable tonicifier in a quantity sufficient to achieve isotonicity with body fluids. The salt is formed in situ during the formulation process. The salt of tartaric acid is preferred; suitable salts for lower concentration dosages are the citric acid and methane sulphonic acid salts.
    Type: Grant
    Filed: September 20, 1990
    Date of Patent: November 5, 1991
    Assignee: Syntex Pharmaceuticals, Ltd.
    Inventors: Alastair B. Selkirk, Michael J. Dey
  • Parenteral formulations of 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl )piperazine
    Patent number: 4973591
    Abstract: A pharmaceutical formulation suitable for parenteral (preferably intravenous) adminstration includes an effective amount of 1-diphenylmethyl-4-[(2-(4-methylphenyl)-5-methyl-1H-imidazol-4-yl)methyl]p iperazine and a suitable amount of an acid to generate a pharmaceutically acceptable salt having a pH above about 3.0 and a solubility above about 4.0 mg/ml. The intravenous formulation optionally includes a suitable tonicifier in a quantity sufficient to achieve isotonicity with body fluids. The salt is formed in situ during the formulation process. The slat of tartaric acid is preferred; suitable salts for lower concentration dosages are the citric acid and methane sulphonic acid salts.
    Type: Grant
    Filed: October 21, 1988
    Date of Patent: November 27, 1990
    Assignee: Syntex Pharmaceuticals, Ltd.
    Inventors: Alastair B. Selkirk, Michael J. Dey
  • Method of preparing long acting formulation
    Patent number: 4940556
    Abstract: A long acting sustained release pharmaceutical composition for dihydropyridine calcium channel blockers wherein the calcium channel blocker and a pH-dependent binde are intimately admixed in essentially spherically shaped non-rugose particles of up to 1.2 mm in diameter.
    Type: Grant
    Filed: July 26, 1987
    Date of Patent: July 10, 1990
    Assignee: Syntex (U.S.A.) Inc.
    Inventors: Calum B. MacFarlane, Alastair B. Selkirk, Michael J. Dey